Co-administration of resveratrol and lipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusion

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Saleh, Monique C ^a   Connell, Barry J ^a   Rajagopal, Desikan ^c   Khan, Bobby V ^a,c   Abd El Aziz, Alaa S ^b   Kucukkaya, Inan ^b   Saleh, Tarek M ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^b UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^c Carmel BioSciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL; THIOCTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; FEASIBILITY STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; RAT; REPERFUSION INJURY; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; STILBENES; STROKE; THIOCTIC ACID;

EID: 84900449200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087865     Document Type: Article

References (37)

1. Wang M, Iliff J, Liao Y, Chen MJ, Shinseki MS, et al. (2012) Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts. J Neuroscience 32(50): 17948-17960.
2. Ginsberg MD (2008) Current status of neuroprotection for cerebral ischemia: Synoptic overview. Stroke 40: S111-S114.
3. Lipton P (1999) Ischemic cell death in brain neurons. Physiological Reviews 79: 1431-1568.
4. He L, Liu B, Dai Z, Zhang HF, Zhang YS, et al. (2012) Alpha lipoic acid protects heart against myocardial ischemia-reperfusion injurt through a mechanism involving aldehyde dehydrogenase 2 activation. Eur J Pharmacology 678: 32-38.
5. Yan Y, Yang J, Chen G, Mou Y, Zhao Y, et al. (2011) Protection of resveratrol and its analogues against ethanol-induced oxidative DNA damage in human peripheral lymphocytes. Mutation Research 721: 171-177.
6. de la Lastra CA, Villegas I (2005) Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Molecular Nutrition and Food Research 49: 405-430.
7. Delmas D, Jannin B, Latruffe N (2005) Resveratrol: preventing properties against vascular alterations and ageing. Molecular Nutrition and Food Research 49: 377-395. (Pubitemid 40780387)
8. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, et al. (2007) Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4: 25.
9. Kang OH, Jang HJ, Chae HS, Oh YC, Choi JG, et al. (2009) Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol Res. 59: 330-7.
10. Saleh MC, Connell BJ, Saleh TM (2013) Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ER alpha and ER beta. Neurosci. Lett., 548: 217-221.
11. Biewenga GP, Haenen GRM, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharm 29: 315-331.
12. Connell BJ, Saleh M, Khan BV, Saleh TM (2011) Lipoic acid protects against reperfusion injury in the early stages of cerebral ischemia. Brain Res. 1375: 128-136.
13. Richard MJP, Connell BJ, Khan BV, Saleh TM (2011) Cellular mechanisms by which lipoic acid confers protection during the early stages of cerebral ischemia: a possible role for calcium. Neurosci. Res. 69: 299-307.
14. Clark WM, Rinker LG, Lessov NS, Lowery SL, Cipolla MJ (2001) Efficacy of antioxidant therapies in transient focal ischemia in mice. Stroke 32: 1000-1004. (Pubitemid 32285174)
15. Panigrahi M, Sadguna Y, Shivakumar BR, Kolluri SVR, Roy S, et al. (1996) α-Lipoic acid protects against reperfusion injury following cerebral ischemia. Brain Res. 717: 184-188. (Pubitemid 26153450)
16. Wolz P, Krieglstein J (1996) Neuroprotective effects of α-Lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacol. 35: 369-375. (Pubitemid 26172069)
17. Cao XH, Phillis JW (1995) The free radical scavenger α-lipoic acid protects against cerebral ischemia-reperfusion injury in gerbils. Free Radical Res 23: 365-370.
18. Mukherjee R, Banerjee S, Joshi N, Singh PK, Baxi D, et al. (2011) A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmium-induced oxidative damage. Cardiovasc. Toxicol. 11: 78-88.
19. Garcia-Estrada J, Gonzalez-Perez O, Gonzalez-Castaneda RE, Martinez-Contreras A, Luquin S, et al. (2003) An alpha-lipoic acid-vitamin E mixture reduces post-embolism lipid peroxidation, cerebral infarction, and neurological deficit in rats. Neurosci. Res. 47: 219-224. (Pubitemid 37152458)
20. Sola S, Mir MQS, Cheema FA, Khan-Merchant N, Menon RG, et al. (2005) Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Results of the Irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study. Circ. 111: 242-248.
21. Shotton HR, Broadbent S, Lincoln J (2004) Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with α-lipoic acid and evening primrose oil. Autonomic Neurosci.: Basic and Clinical 111: 57-65. (Pubitemid 38510615)
22. Gonzalez-Perez O, Gonzalez-Castaneda RE, Heurta M, Luquin S, Gomez-Pinedo U, et al. (2002) Beneficial effects of α-lipoic acid plus vitamin E on neurological deficit, reactive gliosis and neuronal remodeling in the penumbra of the ischemic rat brain. Neurosci. Lett. 321: 100-104. (Pubitemid 34185508)
23. Connell BJ, Saleh TM (2012) Co-administration of apocynin with lipoic acid enhances neuroprotection in a rat model of ischemia/reperfusion. Neurosci. Lett. 507(1): 43-46.
24. Connell BJ, Saleh TM (2010) A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery. J. Neurosci. Methods 190: 28-33.
25. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol. Sci. 82(2): 614-619. (Pubitemid 39600090)
26. Rocha KKR, Souza GA, Ebaid GX, Seiva FRF, Cataneo AC, et al. (2009) Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food and Chemical Toxicology 47(6): 1362-1367.
27. Galati G, Sabzevari O, Wilson JX, O'Brien PJ (2002) Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 177: 91-104. (Pubitemid 34786247)
28. Ahmed A, Asad SF, Singh S, Hadi SM (2000) DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett. 154: 29-37. (Pubitemid 30229906)
29. Chun YJ, Kim MY, Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 262: 20-24. (Pubitemid 29412616)
30. Ibrahimpasic K (2013) Alpha lipoic acid and glycaemic control in diabetic neurophathies at type 2 diabetes treatment. Med. Arh. 67(1): 7-9.
31. Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, et al. (2013) The effect of lipoic acid therapy on cognitive functioning in patients with alzheimer's disease. J. Neurodegen. Diseases 2013: ID 454254, 7 pages.
32. Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, et al. (2013) α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 335(2): 472-478.
33. Gulcin I (2010) Antioxidant properties of resveratrol: a structure-activity insight. Innov. Food Sci. Emerg. Tech. 11: 210-218.
34. Valdecantos MP, Perez-Matute P, Quintero P, Martinez JA (2010) Vitamin C, resveratrol and lipoic acid actions on isolated rat liver mitochondria: all antioxidants but different. Redox Rep. 15(5): 207-216.
35. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM (2004) Lipoic acid as a potential therapy for chronic disease associated with oxidative stress. Curr. Med. Chem. 11: 1135-1146. (Pubitemid 38585058)
36. Bilska A, Wlodek L (2005) Lipoic acid - the drug of the future? Pharmacol. Reports 57: 570-577.
37. Jin J, Sklar GE, Oh VMS, Li SC (2008) Factors affecting therapeutic compliance: a review from the patient's perspective. Therapeutics and Clinical Risk Management 4(1): 269-286. (Pubitemid 351460951)